title: Cancer of the Prostate Risk Assessment (CAPRA) Preoperative Score Versus Postoperative Score (CAPRA-S): ability to predict cancer progression and decision-making regarding adjuvant therapy after radical prostatectomy.
abstract: The University of California, San Francisco, announced in 2011 Cancer of the Prostate Risk Assessment Postsurgical (CAPRA-S) score which included pathologic data, but there were no results for comparing preoperative predictors with the CAPRA-S score. We evaluated the validation of the CAPRA-S score in our institution and compare the result with the preoperative progression predictor, CAPRA score. Data of 130 patients were reviewed who underwent radical prostatectomy for localized prostate cancer from 2008 to 2013. Performance of CAPRA-S score in predicting progression free probabilities was assessed through Kaplan Meier analysis and Cox proportional hazards regression test. Additionally, prediction probability was compared with preoperative CAPRA score by logistic regression analysis. Comparing CAPRA score, the CAPRA-S score showed improved prediction ability for 5 yr progression free survival (concordance index 0.80, P = 0.04). After risk group stratification, 3 group model of CAPRA-S was superior than 3 group model of CAPRA for 3-yr progression free survival and 5-yr progression free survival (concordance index 0.74 vs. 0.70, 0.77 vs. 0.71, P < 0.001). Finally the CAPRA-S score was the more ideal predictor concerned with adjuvant therapy than the CAPRA score through decision curve analysis. The CPARA-S score is a useful predictor for disease progression after radical prostatectomy.
authors.affiliation: Department of Urology, Busan Paik Hospital, Inje University, Busan, Korea.
authors.forename: Won Ik
authors.identifier: 0000-0002-3004-101X
authors.initials: WI
authors.lastname: Seo
authors.affiliation: Department of Urology, Busan Paik Hospital, Inje University, Busan, Korea.
authors.forename: Pil Moon
authors.initials: PM
authors.lastname: Kang
authors.affiliation: Department of Urology, Busan Paik Hospital, Inje University, Busan, Korea.
authors.forename: Dong Il
authors.initials: DI
authors.lastname: Kang
authors.affiliation: Department of Urology, Busan Paik Hospital, Inje University, Busan, Korea.
authors.forename: Jang Ho
authors.initials: JH
authors.lastname: Yoon
authors.affiliation: Department of Urology, Busan Paik Hospital, Inje University, Busan, Korea.
authors.forename: Wansuk
authors.initials: W
authors.lastname: Kim
authors.affiliation: Department of Urology, Busan Paik Hospital, Inje University, Busan, Korea.
authors.forename: Jae Il
authors.identifier: 0000-0002-8114-1125
authors.initials: JI
authors.lastname: Chung
mesh_terms: D003131:Combined Modality Therapy; D003657:Decision Making; D018450:Disease Progression; D018572:Disease-Free Survival; D006801:Humans; D053208:Kaplan-Meier Estimate; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011184:Postoperative Period; D016016:Proportional Hazards Models; D017430:Prostate-Specific Antigen / Q000032:analysis; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D012189:Retrospective Studies
chemical_list: D017430:Prostate-Specific Antigen
keywords: Disease Progression; Prostatectomy; Prostatic Neoplasms; Recurrence